AGAP2 and adenocarcinoma: TBILA showed notable discriminatory capacity for all NSCLC patients, stage I NSCLC patients and adenocarcinoma (ADC) patients, while AGAP2-AS1 exhibited a higher AUC in distinguishing LUSC patients from healthy controls.